8.60 USD
▼-0.02-0.23%
盘后 8.61 +0.09%
2026-09-15
市值
$1.18B
市盈率
—
EPS
-1.83
股息率
—
52 周区间
5.67 – 12.41
成交量
355.79K
Beta
1.33
目标价
17.63
52W 低 5.6752W 高 12.41
价格走势
公司简介
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy produ...